# A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies

> **NCT03922204** · PHASE1 · COMPLETED · sponsor: **Merus B.V.** · enrollment: 72 (actual)

## Conditions studied

- Advanced Cancer
- Solid Tumor, Adult
- B-cell Lymphoma, Adult

## Interventions

- **DRUG:** MCLA-145
- **DRUG:** Pembrolizumab (Keytruda)

## Key facts

- **NCT ID:** NCT03922204
- **Lead sponsor:** Merus B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-05-08
- **Primary completion:** 2024-11-07
- **Final completion:** 2024-11-07
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2024-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03922204

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03922204, "A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT03922204. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*